MYCODART

MycoDART Inc., is the developer of molecular diagnostic tests for the rapid detection of deadly infections in very vulnerable patients such as transplant, cancer, and AIDS. Their team has dozens of years experience in business management, laboratory operations, and molecular diagnostics development. They are in the pre-launch stage for MycoDART-PCR Candida Panel. This test will identify Invasive Candidiasis infections earlier and with higher reliability than the current standard of care. As such, it will reduce mortality and cost of treatment for thousands of patients. A panel for Invasive Aspergillosis will follow.